Health Care • Biotechnology: Pharmaceutical Preparations
$0.83 ▲ +0.00
(+0.35%)
MKT CAP: $4.7M • VOL: 211.8K
52W L $1 52W H $5
ROARABLE / RQD
D- • 42/100
PIOTROSKI
3 / 9
IMNN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$14.7M | -$19.1M | -$21.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | $14.5M | -$18.6M | -$19.5M |
| EBITDA (Normalized) | -$14.4M | -$19.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$13.9M | -$18.9M | -$19.0M |
| Capital Expenditures (CapEx) | $280.6K | $29.5K | — |
| Free Cash Flow (FCF) | -$14.2M | -$18.9M | -$19.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $8.8M | $5.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $7.1M | $4.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IMNN.